Header image for the current page Using in-reach pharmacists to accelerate uptake of biosimilars

Using in-reach pharmacists to accelerate uptake of biosimilars

Arden & GEM’s medicines optimisation team identified an opportunity for South Warwickshire Clinical Commissioning Group (CCG) to boost its QIPP savings plan by accelerating the uptake of biosimilars to treat rheumatological conditions.

Utilising an innovative in-reach model, the CSU provided a pharmacist independent prescriber to support the local acute trust; delivering the expertise, capacity and proven approach to undertake biosimilar treatment switches. In less than five months, the pharmacist had contacted and prescribed biosimilars for 169 patients, contributing over £750,000 in cost savings.

The challenge

Following publication of the ‘Commissioning framework for biological medicines’ in 2017, there has been an NHS-wide drive to embrace the use of best value biological medicines, including ‘biosimilars’. Biosimilars are drugs that are similar – in terms of quality, safety and efficacy – to an original licensed biological product but are often available at a much lower price to the NHS. These drugs can be produced once an original product’s patent has expired and their use is approved by the European Medicines Agency.

By prescribing best value biological medicines to new patients and switching existing patients onto these medicines, NHS England and NHS Improvement estimated that savings of up to £300m per year could be realised by 2020/21.

Our approach

As part of the medicines optimisation service provided to South Warwickshire CCG, Arden & GEM identified an opportunity to support the CCG in achieving its medicines optimisation QIPP savings plan by accelerating the uptake of biosimilars.

The CSU team proposed an innovative in-reach model to facilitate biosimilar switching, working in close partnership with South Warwickshire NHS Foundation Trust (SWFT). By providing prescribing and biosimilar expertise and capacity, in the focus specialty of rheumatology, the objectives of the project were to:

Engaging with stakeholders
Once the project governance and information governance requirements had been satisfied, the next step was to engage with stakeholders at both the Trust and the CCG; including finance leads, the high cost drug pharmacist and the rheumatology team. This was undertaken by Arden & GEM’s pharmacist and was pivotal to the success of this model.

Throughout the project the CSU pharmacist continued to act as a conduit to increase collaboration between the CCG, Trust and clinical specialists which has helped to develop ongoing positive working relationships.

Our pharmacist, who is an independent prescriber, then worked closely with the clinical lead for rheumatology to increase her pharmacy knowledge in this specialist area. This included shadowing, research and on-the-job training to demonstrate competence and gain the confidence of the rheumatology team.

Undertaking phase one
Over a six-week period, the in-reach pharmacist focused on identifying patients with rheumatoid arthritis who would be suitable for adalimumab biosimilars. A patient list was compiled, and letters were sent to those currently undergoing adalimumab treatment to explain what biosimilars are, why they are used within the NHS and why the switch would be beneficial. Over 131 (87%) patients were switched to biosimilars with savings for 2019/20 expected to be in the region of £681,000.

Running phase two
Following the success of the adalimumab project, the CCG commissioned Arden & GEM to undertake a second phase – lasting three months – for patients with rheumatoid arthritis being treated with rituximab. As with phase one, a patient list was compiled, and letters were sent out. However, these switches were more complex as rituximab is administered by infusion (whereas adalimumab is administered by home injection) and the first two infusions need to be given at a slower rate.

The CSU pharmacist followed up each letter with a telephone consultation to explain the proposed change, answer any queries and ensure patients were happy with the switch. The outcome of each telephone consultation was logged in the patient notes and day unit booking-in system so that all consultants and nursing staff were aware of any change.

As a result, 73% of patients contacted agreed to the switch which will correlate to savings of £95,000 in 2019/20, based on each patient receiving two doses.

The outcomes

The overall project has made a significant contribution to South Warwickshire CCG’s medicines optimisation QIPP savings plan, with the following savings expected:

Cost savings in 2019/20

"This success has been achieved due to the enthusiastic work of our team, with the help of the high cost drugs in-reach pharmacist… Thanks again for all the hard work you did here in Rheumatology."

Shirley Rigby – Consultant Rheumatologist at South Warwickshire NHS Foundation Trust

What next?

Following the success of the in-reach model for rheumatology, the approach has been commissioned for a further six months to work alongside endocrinology, dermatology and gastroenterology departments, with a focus on biosimilar switches, prescribing practices and treatment pathways.

The project has also been presented at an STP integration workshop, following which other local CCGs and the NHS England Regional Chief Pharmacist are keen to adopt and extend the model and approach used.

"Initial uptake of biosimilar adalimumab in West Midlands acute trusts was most rapid at Shrewsbury and Telford Hospitals NHS Trust followed by South Warwickshire NHS Foundation Trust."

Richard Seal – Regional Chief Pharmacist for Midlands and East of England